Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if you are waiting for pete to be gone he has another year of stealing from the shareholders coffers, they call it extenuating circumstances.
and if tang is doing this, it is highly illegal unless you are paying the sec under the table to look the other way as many do
I still think Tang is keeping PG around simply to take all the arrows from shareholders while Tang waits comfortably in the background.
Although I wish PG were gone, a part of me is thinking that as soon as he is gone (which would mean that Tang is ready to make his move) we will all be complaining about a lowball "take under" led by Tang.
Surprised because I would have thought that Tang would have cut loose a long time ago
Petey is like covid, we need a vacine. Someday the shareholder will get rid of him.....
Not sure but possible it would mean progressing with phase Ii trials which would mean more money spent.
So.....why would the stock drop 8% this morning after a supposedly positive Phase 1 report on Aur200 yesterday? Do the side effects bother anyone?
bring out the cheerleaders from their hiding places!
chances are pete will be winning the nobel peace price and be man of the year, at least from the shorts perspective.
The end will be
After pete has sucked all the money out of the shareholders coffers and placed it in his own account.
multiple years going and I am still correct about mr peter principle.
They will keep this up to the end.
Never say never cervelo, I can’t believe your still here, have you made up with your brother yet?
Anybody know what is causing the high volume and large increase in SP today?
I guess that activist (name eludes me) hasn't been able to get this co sold.
AUPH back to $6 and maybe I will buy in again. Just so sad the CEO is still in the CEO.
since this stock will never be worth more than 8.00 as long a pete is the ceo I would
settle seeing pete in jail for being the bernie madoff of AUPH.
since this stock will never be worth more than 8.00 as long a pete is the ceo I would
settle seeing pete in jail for being the bernie madoff of AUPH.
You are righf about that, but to fair L's uptake no where resembles a hockey stick. 1st qtr pretax profit of 24 million. Doesn't Pete make more than that. Should have been sold before demonstrating how difficult it is to sell the drug.
AUPH!! Like Rodney Dangerfield would say, AUPH gets no respect,
Funny, His wife made the same comment,
Don't listen to the doubters, Pete's got the goods and will deliver the prize to your brokerage accounts.. He starts slow, but finishes strong. Like Glickman...
the market seems to be growing and pete is just leaving us behind.
for some reason this crook believes this is his private company he started, with his own money and owes no one a any reasoning as to why he is so ill prepared to be a ceo.
I do not think this is about market growth just a free paycheck
This is all about the growth rate of this market. Folks, this isn't a new cancer drug....
I think, heck I know, Pete's team that recruited him for the position did a terrific job, and were handsomely rewarded for their efforts.. well done, Pete.
@biotech researcher: I'm certainly not the person to offer self help advice. However, Cervelo is 💯right. Greenleaf has failed AUPH and shareholders. He's also correct, the guy is grossly overpaid and deserving of a substantial pay cut if he manages to hang on here.
A quality mgmt team would have this trading at 20+ without a buyout. The company needs a large disrupter shareholder to apply pressure for a management shakeup.
lol
surely you don't think paying pettie another 10 million plus for another year will make a value towards shareholder value. I am dropping my expectations down to 10.50 to get out to many companies out there where a return on investment is possible. auph stock is like driving to idaho to buy a lottery ticket and think something will happen. though a lottery ticket may just have a better chance than we do here.
Cervelo, for your well being, please step away from the board for two months. I promise you that you will be a new man, with an incredible future..
some people love to wake up to the smell of fresh coffee in the morning
not me I wake up to enjoy the burning of good money, keep up the good work smokey the bearpete
Great run on upbeat earnings.
the market does not care about auph as long as pettie is making 20 times what the president gets paid.
Great call. Buy back. Cashflow great. Profitability. Congratulations Jess.
Is Lupy sold outside the US ? Trump wants to match the lowest price paid on drug outside the US
President Donald Trump said he plans to order a cut in US prescription drug costs by mandating that Americans pay no more than people in countries that have the lowest price.
Is the executive order coming out tomorrow that is supposed to drop US drug prices by 30% to 80% gonna tank pharma/bio stocks? When the gov sees the margin on Lupy their eyes will light up.
Kind of like pelosi, vote for the bill and you can read it later, "Trust us"
Annual Meetings usually allow shareholders to attend in person. This group obviously doesn't want to hear "it", so it's being done only in a virtual format.
He is what a 10.6 million dollar gets you in a crooked ceo
“When Glass Lewis first recommended a proxy stance for Aurinia on June 19, 2019, Aurinia’s market capitalization was approximately $1.84 billion, and its enterprise value was about $1.665 billion. As of April 30, 2025, the market capitalization is $1.114 billion, and the enterprise value is $765.3 million, representing declines of 39.5% and 54.0%, respectively.”
don't even want to think of it adjusted with inflation
remember vote early and often, a vote for petie is a vote for the same nothingness. 10 million a year pay package and only his middle finger has been lifted towards the shareholders
Got my proxies today.
I voted yes for Tang, no on all the other directors, yes on the auditor, yes on "say for pay", and no on increasing the pool of shares for stock compensation.
Time is still on their side, almost 12 more years of patent exclusivity. It will Cerv. Let’s forget our banters. We’re all rooting for the stuff, profit.
thank you, still waiting to see if auph gets resurrected.
fools and their money are soon parted.
some people may be riding on free shares from the crooked ceo
I have no doubt that Pete has got this guy on speed dial:https://finance.yahoo.com/news/alis-biosciences-launches-fund-free-070000220.html
Remember, Jess said he will still be here even if it drops to $2.
this part is a joke!
We have redesigned our employee equity incentive program to strengthen its alignment with shareholder interests.
petie has never done anything that is linked to shareholder interests,
all he had done is steal the shareholders funds
...what do you expect regarding a buyout?
I know Ariad, and I know Aurinia. Aurinia is no Ariad..
insiders may buy, yet the real crook sells
PETER GREENLEAF (Chief Executive Officer) has made 0 purchases and 2 sales selling 360,540 shares for an estimated $2,871,124.
He probably has never paid for any shares of this company he is just a worthless boat anchor. From 34.00+ stock, petie can't even get it up to 12.5 so I can run
I wish some insider would buy out PG's employment contract...
Followers
|
219
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
17713
|
Created
|
04/23/10
|
Type
|
Free
|
Moderators |
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |